journal
Journals Breast Cancer Research and Tre...

Breast Cancer Research and Treatment

https://read.qxmd.com/read/38904892/real-world-use-patterns-effectiveness-and-tolerability-of-sacituzumab-govitecan-for-second-line-and-later-line-treatment-of-metastatic-triple-negative-breast-cancer-in-the-united-states
#1
JOURNAL ARTICLE
Kevin Kalinsky, Laura Spring, Clinton Yam, Manali Ajay Bhave, Ioanna Ntalla, Catherine Lai, Nikoleta Sjekloca, Brian Stwalley, Michael Stokes, Aliki Taylor, Rita Nanda
PURPOSE: Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and limited treatment options. Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is approved for patients with mTNBC who have received ≥ 2 systemic therapies (≥ 1 in the metastatic setting) based on the ASCENT study (NCT02574455). The current study describes real-world SG use and outcomes in patients with mTNBC in the United States. METHODS: This retrospective, observational study included adult patients with mTNBC from the ConcertAI Patient360™ database who received SG in the second line (2L) and later from April 2020 to May 2022...
June 21, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38900213/characteristics-of-chinese-breast-cancer-patients-with-double-heterozygosity-for-brca1-and-brca2-germline-pathogenic-variants
#2
JOURNAL ARTICLE
Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie
PURPOSE: Despite of very rare, breast cancer patients with double heterozygosity (DH) variants in BRCA1 and BRCA2 genes have been identified in other ethnic groups and seem to be associated with distinctive phenotypes. However, little is known about the frequency and clinical characteristics of Chinese breast cancer patients with BRCA1/2 DH variants. METHODS: Four hundred and eleven unrelated patients with BRCA1 or BRCA2 pathogenic variants (PVs) were identified in a large series of unselected breast cancer patients...
June 20, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38900212/p53-protein-expression-patterns-associated-with-tp53-mutations-in-breast-carcinoma
#3
JOURNAL ARTICLE
Sarah A Anderson, Brooke B Bartow, Shuko Harada, Gene P Siegal, Shi Wei, Valeria L Dal Zotto, Xiao Huang
PURPOSE: The importance of a TP53 mutation has been demonstrated in several tumor types, including breast cancer (BC). However, the accuracy of p53 protein expression as a predictor of gene mutation has not been well studied in BC. Therefore, we evaluated p53 protein expression associated with TP53 mutations in breast cancers from 64 patients. METHODS: TP53 mutation was examined using next-generation sequencing (NGS). p53 protein expression was examined using immunohistochemistry (IHC)...
June 20, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38898360/reliability-of-magseed%C3%A2-marking-before-neoadjuvant-systemic-therapy-with-subsequent-contrast-enhanced-mammography-in-patients-with-non-palpable-breast-cancer-lesions-after-treatment-the-magma-study
#4
JOURNAL ARTICLE
Eva Iglesias Bravo, Antonio Mariscal Martínez, Helena Peris Alvà, Diego Riol Sancho, José Carlos Antela López, Joel Aranda Sánchez, Pilar Escobar Casa, Cristina Gómez de Las Heras, María Antonia Fernández Venegas, Eduarda García Vidal, Elisabeth Delgado Begines, Carmen García Mur, Isabel Vicente, Carmen Casamayor, Silvia Cruz, Anabel García Barrado
PURPOSE: To assess the reliability of excising residual breast cancer lesions after neoadjuvant systemic therapy (NAST) using a previously localized paramagnetic seed (Magseed®) and the subsequent use of contrast-enhanced spectral mammography (CESM) to evaluate response. METHODS: Observational, prospective, multicenter study including adult women (> 18 years) with invasive breast carcinoma undergoing NAST between January 2022 and February 2023 with non-palpable tumor lesions at surgery...
June 20, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38896334/bet-directed-protacs-in-triple-negative-breast-cancer-cell-lines-mda-mb-231-and-mda-mb-436
#5
JOURNAL ARTICLE
Maryana Teufelsbauer, Sandra Stickler, Marie-Therese Eggerstorfer, Dennis Clyde Hammond, Gerhard Hamilton
PURPOSE: This study aims to find whether the proliferation and migration of triple negative breast cancer (TNBC) cell lines can be reduced by treatment with bromodomain and extra-terminal domain (BET) inhibitor JQ1 and BET protein targeting chimeras (PROTACs) ARV-771 and MZ1. METHODS: Cytotoxicity tests, scratch migration assays and western blot proteome profiler arrays for protein expression of cancer-related proteins were used to evaluate the impact of a BET-inhibitor and two BET-directed PROTACs on cell viability, migration and on protein expression...
June 19, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38896333/a-novel-role-of-igfbp5-in-the-migration-invasion-and-spheroids-formation-induced-by-igf-i-and-insulin-in-mcf-7-breast-cancer-cells
#6
JOURNAL ARTICLE
Karem Rodríguez-Rojas, Pedro Cortes-Reynosa, Pablo Torres-Alamilla, Nínive Rodríguez-Ochoa, Eduardo Perez Salazar
PURPOSE: The insulin-like growth factor (IGF) system includes IGF-I, IGF-II insulin and their membrane receptors. IGF system also includes a family of proteins namely insulin-like growth factor-binding proteins (IGFBPs) composed for six major members (IGFBP-1 to IGFBP6), which capture, transport and prolonging half-life of IGFs. However, it has been described that IGFBPs can also have other functions. METHODS: IGFBP5 expression was inhibited by shRNAs, migration was analyzed by scratch-wound assays, invasion assays were performed by the Boyden chamber method, spheroids formation assays were performed on ultra-low attachment surfaces, expression and phosphorylation of proteins were analyzed by Western blot...
June 19, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38896332/male-breast-cancer-a-multicenter-study-to-provide-a-guide-for-proper-management
#7
JOURNAL ARTICLE
Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti
INTRODUCTION: To offer an extensive retrospective experience on the management of male breast cancer. METHODS: A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data...
June 19, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38888797/baseline-gut-microbiota-as-a-predictive-marker-for-the-efficacy-of-neoadjuvant-chemotherapy-in-patients-with-early-breast-cancer-a-multicenter-prospective-cohort-study-in-the-setouchi-breast-project-14
#8
JOURNAL ARTICLE
Shogo Nakamoto, Yukiko Kajiwara, Kohei Taniguchi, Akira I Hida, Yuichiro Miyoshi, Takanori Kin, Mari Yamamoto, Daisuke Takabatake, Shinichiro Kubo, Hajime Hikino, Yutaka Ogasawara, Masahiko Ikeda, Hiroyoshi Doihara, Tadahiko Shien, Naruto Taira, Takayuki Iwamoto, Shinichi Toyooka
PURPOSE: Various studies have demonstrated the causal relationship between gut microbiota and efficacy of chemotherapy; however, the impact of gut microbiota on breast cancer has not been fully elucidated. This study aimed to evaluate the associations between the gut microbiota before neoadjuvant chemotherapy and its consequent efficacy in breast cancer. METHODS: This prospective observational study included patients who received neoadjuvant chemotherapy for primary early breast cancer at eight institutions between October 1, 2019, and March 31, 2022...
June 18, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38888796/demographic-and-clinical-characteristics-of-patients-with-metastatic-breast-cancer-and-leptomeningeal-disease-a-single-center-retrospective-cohort-study
#9
JOURNAL ARTICLE
Laura A Huppert, Samantha Fisch, Elene Tsopurashvili, Sai Sahitha Somepalle, Mia Salans, Harish N Vasudevan, A Jo Chien, Melanie Majure, Hope S Rugo, Ronald Balassanian, Lauren Boreta, Michelle E Melisko
PURPOSE: Leptomeningeal disease (LMD) is a devastating complication of metastatic breast cancer (MBC). It is critical to better understand the risk factors, natural history, and treatment outcomes, including patients in a modern cohort. METHODS: In this single center retrospective cohort study, we identified patients with MBC and LMD who received care from 2000 to 2024 and abstracted key clinical, treatment, and survival data. RESULTS: We identified 111 patients with MBC and LMD, including patients with the following subtypes: HR+/HER2- (n = 53, 47...
June 18, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38879862/re-surgery-of-the-primary-tumor-in-patients-with-de-novo-metastatic-breast-cancer-a-nationwide-population-based-retrospective-cohort-study-in-belgium-and-the-national-cancer-database-ncdb
#10
LETTER
P Neven, S Han, K Borremans, M Van Houdt, S A Khan
No abstract text is available yet for this article.
June 16, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38878125/pedigree-analysis-exploring-the-inconsistency-between-diverse-phenotypes-and-testing-criteria-for-germline-tp53-mutations-in-chinese-women-with-breast-cancer
#11
JOURNAL ARTICLE
Xin Huang, Chang Chen, Yan Lin, Changjun Wang, Xingtong Zhou, Ying Xu, Qiang Sun, Yidong Zhou
PURPOSE: In the present study, we addressed the inconsistency between the testing criteria and diverse phenotypes for germline TP53 mutation in patients with breast cancer in the Chinese population. METHOD: We proposed a new added item (synchronous or metachronous bilateral breast cancer) as one of the testing criteria (aimed at high-penetrance breast cancer susceptibility genes) and applied it for determining TP53 germline mutation status in 420 female patients with breast cancer using multigene panel-based next-generation sequencing, Sanger sequencing, and mass spectrometry...
June 15, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38877185/incidence-of-local-breast-cancer-recurrence-with-delayed-radiation-therapy
#12
JOURNAL ARTICLE
Hayder Hamza Alabedi, Imad Khalid Ahmed, Ahmed Sabah Mohammed Jamil
BACKGROUND: The purpose of this research was to examine the probability of ipsilateral breast cancer recurrence in individuals whose RT was delayed after the first chemotherapy and surgery. PURPOSE: To analyze the effect of delaying RT for breast cancer patients (by more than 6 weeks after treatment). METHODOLOGY: A retrospective analysis comprised 136 female breast cancer patients treated at the Baghdad Centre for Radiation Oncology and Nuclear Medicine from 2021 to May 2022...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874689/patient-reported-outcomes-and-quality-of-life-after-breast-conserving-surgery-mastectomy-and-breast-reconstruction-assessed-using-the-breast-q-questionnaire
#13
JOURNAL ARTICLE
Shoichi Tomita, Takashi Yoshitake, Noriko Matsunaga, Maiko de Kerckhove, Miwako Fujii, Yasunobu Terao
PURPOSE: Breast-conserving surgery is the preferred treatment for breast cancer; however, its associated risk of local recurrence is higher than that of mastectomy. We performed a comparative analysis of four patient-reported outcomes, psychosocial well-being, sexual well-being, breast satisfaction, and physical well-being of the chest, and quality of life after three surgical approaches, breast-conserving therapy (BCT), mastectomy alone, and mastectomy with breast reconstruction, for breast cancer treatment...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874688/ferroptosis-as-a-promising-targeted-therapy-for-triple-negative-breast-cancer
#14
REVIEW
Kasra Mokhtarpour, Sepideh Razi, Nima Rezaei
PURPOSE: Triple negative breast cancer (TNBC) is a challenging subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Standard treatment options are limited, and approximately 45% of patients develop distant metastasis. Ferroptosis, a regulated form of cell death triggered by iron-dependent lipid peroxidation and oxidative stress, has emerged as a potential targeted therapy for TNBC. METHODS: This study utilizes a multifaceted approach to investigate the induction of ferroptosis as a therapeutic strategy for TNBC...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874687/adherence-to-guideline-recommendations-for-follow-up-in-patients-with-dcis-at-a-large-teaching-hospital-in-the-netherlands
#15
JOURNAL ARTICLE
K K Rajan, J J Nijveldt, S Verheijen, S Siesling, M A Beek, A B Francken
PURPOSE: Ductal-carcinoma in situ (DCIS) is a pre-invasive form of breast cancer with good prognosis. Follow-up guidelines in the Netherlands are currently the same as for invasive breast cancer. Due to fear of invasive breast cancer or recurrence, it is hypothesized that follow-up for DCIS after treatment is more intense in practice resulting in potentially unnecessary high costs. This study investigates the follow-up in practice for patients with DCIS compared to the recommendations in order to inform clinicians and policy makers how to utilize these guidelines...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874686/spectrum-of-germline-pathogenic-variants-in-brazilian-hereditary-breast-ovarian-cancer-cases
#16
JOURNAL ARTICLE
João Paulo Faria, Juliana Godoy Assumpção, Lorena de Oliveira Matos, Fernanda Caroline Soardi, Gabriel Pissolati Mattos Bretz, Eitan Friedman, Luiz De Marco
PURPOSE: To define the spectrum of germline pathogenic variants (PVs) and copy number variant (CNV) in cancer susceptibility genes to the burden of breast and ovarian cancer (BC, OvC) in high-risk Brazilians in Minas Gerais with health insurance, southeast Brazil, undergoing multigene panel testing (MGPT). METHODS: Genotyping eligible individuals with health insurance in the Brazilian healthcare system for Hereditary Breast and Ovarian Cancer Syndrome to undergo molecular testing for 44 or 141-gene panels, a decision that was insurance driven...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874685/the-remar-rhein-main-registry-real-world-study-prospective-evaluation-of-the-21-gene-breast-recurrence-score%C3%A2-assay-in-addition-to-ki-67-for-adjuvant-treatment-decisions-in-early-stage-breast-cancer
#17
JOURNAL ARTICLE
Christian Jackisch, Louiza Anastasiadou, Sebastian Aulmann, Athanasios Argyriadis, Volker Möbus, Christine Solbach, Peter Baier, Dagmar Giesecke, Sven Ackermann, Elke Schulmeyer, Boris Gabriel, Dietrich Mosch, Stephanie Buchen, Eckart Krapfl, Ursula Hurst, Mario Vescia, Hans Tesch, Marc Thill
PURPOSE: Ki-67 is recommended by international/national guidelines for risk stratification in early breast cancer (EBC), particularly for defining "intermediate risk," despite inter-laboratory/inter-observer variability and cutoff uncertainty. We investigated Ki-67 (> 10%- < 40%, determined locally) as a prognostic marker for intermediate/high risk in EBC, pN0-1 patients. METHODS: This prospective, non-interventional, real-world study included females ≥ 18 years, with pN0/pN1mi/pN1, HR+ , HER2-negative EBC, and locally determined Ki-67 ranging 10%-40%...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874684/um171-suppresses-breast-cancer-progression-by-inducing-klf2
#18
JOURNAL ARTICLE
Xiaojuan Ran, Anling Hu, Yi Kuang, Chunlin Wang, Wuling Liu, Xiao Xiao, Eldad Zacksenhaus, Xiangdi Yu, Yaacov Ben-David
PURPOSE: Breast cancer is the most frequent cancer in women with significant death rate. Morbidity is associated with drug resistance and metastasis. Development of novel drugs is unmet need. The aim of this study is to show potent anti-neoplastic activity of the UM171 compound on breast cancer cells and its mechanism of action. METHODS: The inhibitory effect of UM171 on several breast cancer (BC) cell lines was examined using MTT and colony-forming assays. Cell cycle and apoptosis assays were utilized to determine the effect of UM171 on BC cell proliferation and survival...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38874683/tamoxifen-modulates-nutrition-deprivation-induced-er-stress-through-ampk-mediated-er-phagy-in-breast-cancer-cells
#19
JOURNAL ARTICLE
Biswas Bidisha, Manickavasagan Sowmya, Suchita Shalini, Chandrasekaran Mythri, Anshu Gupta, Gangipangi Vijayakumar, Selvaraju Sudhagar
PURPOSE: Rapid proliferation and nutrition starvation in the tumor microenvironment pose significant challenges to cellular protein homeostasis. The accumulation of misfolded proteins in the endoplasmic reticulum lumen induces stress on cells and causes irreversible damage to cells if unresolved. Emerging reports emphasize the influence of the tumor microenvironment on therapeutic molecule efficacy and treatment outcomes. Hence, we aimed to understand the influence of tamoxifen on the cellular adaptation to endoplasmic reticulum stress during metabolic stress in breast cancer cells...
June 14, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38872062/comprehensive-genomic-profiling-of-esr1-pik3ca-akt1-and-pten-in-hr-her2-metastatic-breast-cancer-prevalence-along-treatment-course-and-predictive-value-for-endocrine-therapy-resistance-in-real-world-practice
#20
JOURNAL ARTICLE
Manali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, Gerald Li, Takara Scott, Jeffrey S Ross, Lincoln Pasquina, Richard S P Huang, Heather McArthur, Mia A Levy, Ryon P Graf, Kevin Kalinsky
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(-) MBC. METHODS: Records from a de-identified breast cancer clinicogenomic database for patients who underwent TBx/LBx testing at Foundation Medicine during routine clinical care at ~ 280 US cancer clinics between 01/2011 and 09/2023 were assessed...
June 14, 2024: Breast Cancer Research and Treatment
journal
journal
28253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.